Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

DOI: https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma

Blood (2021) 138 (Supplement 1): 3526.

DOI: https://doi.org/10.1182/blood-2021-154172

Published: 2021

Journal Articles

Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma

Dai Chihara, Loretta Nastoupil, Paolo Strati, Felipe Samaniego, Lei Feng, Maria Alma Rodriguez, Luis Fayad, Jason R. Westin, Fredrick B. Hagemeister, Michael Wang, Sattva S. Neelapu, Nathan H. Fowler

Blood (2021) 138 (Supplement 1): 3532.

DOI: https://doi.org/10.1182/blood-2021-149293

Published: 2021

Journal Articles

Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL

Jason R. Westin, Raphael Steiner, Lei Feng, Paolo Strati, Christopher R. Flowers, Sattva S. Neelapu, Loretta Nastoupil, Dai Chihara, Fredrick B. Hagemeister, Sairah Ahmed, Ranjit Nair, Luis Fayad, Hun Ju Lee, Maria Alma Rodriguez, Eric Davis, Michael R Green

Blood (2021) 138 (Supplement 1): 3572.

DOI: https://doi.org/10.1182/blood-2021-148524

Published: 2021

Journal Articles

Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma

Raphael E Steiner, Paolo Strati, Christopher R. Flowers, Sattva S. Neelapu, Michael R Green, Loretta Nastoupil, Fredrick B. Hagemeister, Lei Feng, Sairah Ahmed, Ranjit Nair, Luis Fayad, Hun Ju Lee, Maria Alma Rodriguez, Jason R. Westin

Blood (2021) 138 (Supplement 1): 1408.

DOI: https://doi.org/10.1182/blood-2021-149616

Published: 2021

Journal Articles

Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series

Blood (2021) 138 (Supplement 1): 1448.

DOI: https://doi.org/10.1182/blood-2021-154035

Published: 2021

Journal Articles

Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2021) 138 (Supplement 1): 3826.

DOI: https://doi.org/10.1182/blood-2021-147488

Published: 2021

Journal Articles

Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion

Blood (2021) 138 (Supplement 1): 1740.

DOI: https://doi.org/10.1182/blood-2021-145503

Published: 2021

Journal Articles

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 38.

DOI: https://doi.org/10.1182/blood-2021-148314

Published: 2021

Journal Articles

A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Anita Kumar, Jason R. Westin, Stephen J. Schuster, Grzegorz S. Nowakowski, Izidore S. Lossos, Devin Copley, Clare Grieve, Allison P. Jacob, Ashlee Joseph, Leana Laraque, Gita Masand, Chelsea D Mullins, Ellen Napier, Tania Rodriguez, Venkatraman Seshan, Shreya Vemuri, Andrew D. Zelenetz

Blood (2021) 138 (Supplement 1): 52.

DOI: https://doi.org/10.1182/blood-2021-150572

Published: 2021

Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2.

DOI: https://doi.org/10.1182/blood-2021-148039

Published: 2021

Journal Articles

Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy

Ajlan Al Zaki, Jason R. Westin, Grace Watson, Lei Feng, Sairah Ahmed, Haleigh Mistry, Loretta Nastoupil, Misha Hawkins, Ranjit Nair, Swaminathan P Iyer, Hun Lee, Raphael E Steiner, Christopher R. Flowers, Elizabeth J. Shpall, Partow Kebriaei, Sattva S. Neelapu, Paolo Strati

Blood (2021) 138 (Supplement 1): 3870.

DOI: https://doi.org/10.1182/blood-2021-146023

Published: 2021

Journal Articles

Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab

Paolo Strati, MD, Felipe Samaniego, MD, Mariana Gallardo, Mansoor Noorani, F. B. B. Hagemeister, MD, Jason R. Westin, MD, Hun Ju Lee, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Jillian R. Gunther, MD PhD, Rashmi Kanagal-Shamanna, MD, Francisco Vega, MDPhD, Nathan H Fowler, MD, Chris R. Flowers, MD MS, Loretta J. Nastoupil, MD

Blood (2020) 136 (Supplement 1): 31–32.

DOI: https://doi.org/10.1182/blood-2020-134120

Published: 2020

Journal Articles

Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival

Hua-Jay J Cherng, MD, Raphael E Steiner, MD, Luis Fayad, Paolo Strati, MD, Ranjit Nair, MD, F. B. B. Hagemeister, MD, Loretta J. Nastoupil, MD, Hun Ju Lee, MD, Sattva S. Neelapu, MD, Christopher Flowers, MDMS, Felipe Samaniego, MD, Maria Alma Rodriguez, MD, Lei Feng, MS, Hubert Chuang, MDPhD, Jason R. Westin, MD

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-134203

Published: 2020

Journal Articles

Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2020) 136 (Supplement 1): 23–24.

DOI: https://doi.org/10.1182/blood-2020-135846

Published: 2020

Journal Articles

Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel

Paolo Strati, MD, Grace Watson, Sandra B. Horowitz, Pharm.D., Ranjit Nair, MD, Maria Alma Rodriguez, MD, Raphael Eric Steiner, MD, Luis Fayad, Jason R. Westin, MD, Sattva S. Neelapu, MD

Blood (2020) 136 (Supplement 1): 16–17.

DOI: https://doi.org/10.1182/blood-2020-135835

Published: 2020

Journal Articles

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Stefan Alig, MD, Charles Macaulay, MSc, BA, David M. Kurtz, MD PhD, Ulrich Dührsen, Prof, MD PhD, Andreas Hüttmann, MD, Michael C. Jin, BS, Brian Sworder, MD PhD, Andrea Garofalo, BS, BA, Mohammad Shahrokh Esfahani, Joanne Soo, MD, Florian Scherer, MD, Alexander Craig, MPhil, Olivier Casasnovas, MD, Jason R. Westin, MD, Gianluca Gaidano, MD PhD, Davide Rossi, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 491.

DOI: https://doi.org/10.1182/blood-2019-129283

Published: 2019

Journal Articles

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1609.

DOI: https://doi.org/10.1182/blood-2019-131499

Published: 2019

Journal Articles

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 765.

DOI: https://doi.org/10.1182/blood-2019-125769

Published: 2019

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

DOI: https://doi.org/10.1182/blood-2019-129422

Published: 2019

NARROW

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma

Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma

Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL

Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma

Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series

Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy

Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab

Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival

Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy

Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only